



Review Article

An Overview of Nicotine Polacrilex Pouches as Nicotine Replacement Therapy

Aakriti Raj¹, Mayank Bansal², Rakesh Kumar Gupta³, Pradeep Kumar Grag⁴

¹Research Scholar, Jaipur College of Pharmacy, Jaipur

²Professor & Principal, Jaipur College of Pharmacy, Jaipur

³Professor, Jaipur College of Pharmacy, Jaipur

⁴Lecturer, Jaipur College of Pharmacy, Jaipur

Article Info: Received: 15-09-2025 / Revised: 27-10-2025 / Accepted: 28-011-2025

Corresponding Author: Aakriti Raj

DOI: <https://doi.org/10.32553/jbpr.v14i6.1381>

Conflict of interest statement: No conflict of interest

Abstract:

Nicotine addiction is the major global health concern, and Nicotine Replacement Therapy (NRT) is the most effective strategy for smoking cessation. There are several types of formulations available for nicotine replacement therapy, which include gums, lozenges, inhalers, patches, and pouches. Several studies indicate that the nicotine polacrilex pouch provides controlled nicotine delivery and reduces the craving intensity. The nicotine polacrilex pouch has emerged as an oral delivery form. The nicotine polacrilex pouch contains pharmaceutical-grade nicotine that makes it distinct from traditional smokeless tobacco alternatives, as they deliver nicotine without a large number of harmful constituents associated with smoking cigarettes.

Keywords: Nicotine polacrilex, Nicotine pouch, Nicotine replacement therapy, Smoking cessation.

Introduction

Nicotine Replacement Therapy carries various strategies, which is aimed at controlling withdrawal symptoms and reducing nicotine dependence, thus resulting in smoking cessation [1]. Earlier, gums, patches, inhalers, nasal sprays, and lozenges were used in NRT. These were all designed to deliver nicotine without the harmful byproducts that are ingested through smoking [2] [3].

Recently, new tobacco and nicotine products have become recognized, such as electronic cigarettes, heated tobacco products, and oral nicotine pouches, which are posing the lower health risks than traditional nicotine products [4]. Among these newer options, nicotine pouches are smokeless and tobacco-free, containing pharmaceutical-grade nicotine absorbed onto a

cellulose matrix within a porous pouch [5]. Specifically, nicotine polacrilex pouches, these contain nicotine-polacrilex complex and a gum base filler which offer a specific formulation that influences nicotine delivery and pharmacokinetic profiles compared to other nicotine pouch variants.

This specific formulation leads to buccal absorption of nicotine, bypassing first-pass metabolism and potentially providing a more rapid and robust nicotine delivery compared to some traditional NRTs [3]. Nicotine Polacrilex primarily acts on certain nicotinic acetylcholine receptors in the brain. It increases Acetylcholine release and metabolism by activating presynaptic acetylcholine receptors. Dopamine levels in the nucleus accumbens rise as a result

of its stimulation of the dopaminergic system. [6] For heavily dependent smokers this enhanced delivery profile is particularly relevant, who often require high concentration of nicotine to effectively manage cravings and achieve cessation [5].

Furthermore, the discreet nature and user convenience of nicotine polacrilex pouches contribute to their acceptability among nicotine users, potentially increasing compliance with

NRT regimens and overall smoking cessation rates [7]

Nicotine Polacrilex Profile: The salt of nicotine with the polymer Amberlite IRP64 is called nicotine polacrilex. Amberlite IRP64 is a copolymer comprising divinylbenzene and methacrylic acid. Nicotine polacrilex can be used as a source of nicotine in nicotine pouch and other oral nicotine delivery products to-solid dilution with microcrystalline cellulose [6]




Figure 1:

Molecular Formula: $[(C_4H_6O_2)_x(C_{10}H_{10})_y](C_{10}H_{14}N_2)$ Synonyms: Nicorette

Nicotine Pouch

A specific kind of dosage form used in nicotine replacement therapy is Pouch. They give nicotine to the body by momentarily lowering cravings and the symptoms of nicotine withdrawal after stopping smoking.

However, Pouch provides a more consistent and lower dose of nicotine to blood than cigarettes do. Pouch helps in managing, controlling, and progressively lessening body's desire for nicotine when taken as prescribed. The good news is that Pouch don't pose the same health risks as cigarettes because they don't contain tar or carbon monoxide. Nevertheless, nicotine, the cigarette's addictive component, is still delivered by the pouch [8]

For a nicotine pouch to be as safe and effective as possible, the patient must adhere to certain instructions. The patient should refrain from eating or drinking throughout the usage of the pouch, according to one of the main directions. The appropriate release and absorption of

nicotine into the circulation may be hampered by food or drink consumption during this time. Specifically, beverages like coffee, juices, or carbonated sodas that lower the pH level in the mouth might drastically decrease buccal absorption. [9] As a result, the pouch's efficiency is reduced since less nicotine is absorbed via the oral mucosa. Patients are recommended to refrain from consuming these drinks for at least fifteen minutes prior to applying a pouch beneath the lip in order to maximize absorption. [10] One pouch should be positioned behind the top lip and left there for around half an hour in order to use it properly. Nicotine is progressively released and absorbed by the mouth's mucous membranes throughout this period. The patient may sometimes use their tongue to gently reposition the pouch, which should rest comfortably in place, to improve the release of nicotine. By stimulating the pouch, this movement can guarantee a more uniform and effective delivery of nicotine for the entire prescribed amount of time. The pouch should be taken out and disposed of appropriately after 30 minutes. [11] By precisely following these instructions, cases can achieve harmonious

nicotine delivery, minimize hindrance from foods and potables, and maximize the remedial benefits

Mechanism of action

The systemic bioavailability of nicotine polacrilex that has been consumed reduces due to the first-passage elimination. After taking the nicotine polacrilex in, it is rare to get the high and quickly increasing nicotine concentrations that are seen after smoking. The liver is the primary site of nicotine metabolism, with an average plasma clearance rate of around 70 l/h. The kidneys and lungs also process nicotine polacrilex. [8]

Pharmacokinetic properties:

Absorption

The amount of nicotine polacrilex released in the oral cavity and the amount consumed determine how much of the released nicotine polacrilex is absorbed from an oral dosage form. The buccal mucosa absorbs the majority of the nicotine polacrilex that is emitted. First-passage elimination reduces the systemic bioavailability of nicotine polacrilex that has been consumed. [12]

Distribution

Nicotine polacrilex has a half-life of roughly two hours and a volume of distribution of roughly 2-3 l/kg after intravenous delivery. The kinetics of nicotine polacrilex are not anticipated to be significantly impacted by other illnesses or concurrent drug usage that alter plasma protein levels [12].

Metabolism: The liver is the primary site of nicotine polacrilex metabolism, with an average plasma clearance rate of roughly 70 l/h. The kidneys and lungs additionally break down nicotine. [12]

Elimination

Ten percent or so of nicotine polacrilex is eliminated unaltered in the urine. Increased urine acidification below pH 5 can result in the excretion of up to 30% of nicotine polacrilex [12]

Side Effects:

It includes nausea, salivation, abdominal pain, diarrhea, sweating, headache, dizziness, disturbed hearing and marked weakness.

Common adverse effects vary depending on how nicotine polacrilex is formulated. Nicotine toxicity and ongoing addiction are serious dangers. They don't seem to make heart attacks more likely. If taken during pregnancy, there may be risks to the unborn child. Reducing cravings brought on by nicotine addiction is how nicotine replacement therapy functions. [13]

Conclusion

Nicotine addiction has emerged to be one of the most serious global public health concerns, worldwide, resulting in millions of deaths each year due to tobacco-related diseases. Nicotine Replacement Therapy (NRT) has appeared as one of the most effective and evidence-based pharmacological metho for smoking cessation. Over the years, many dosage forms such as gums, lozenges, inhalers, nasal sprays, and transdermal patches have been developed to deliver nicotine in a controlled manner than smoking cigarettes. The development of nicotine Polacrilex pouches shows a enhanced convenience in oral nicotine delivery systems, combining pharmaceutical precision with enhanced convenience for patients.

Nicotine polacrilex is a chemically stable nicotine-resin complex, formed with the polymer Amberlite IRP64, a copolymer of methacrylic acid and divinylbenzene. Due to this ion-exchange resin system, it allows a controlled and sustained release of nicotine when it is exposed to saliva, reducing the sharp plasma nicotine spikes generally seen in cigarettes. In nicotine polacrilex pouches formulation, the complex is formulated inside a soft, porous cellulose matrix, allowing for buccal absorption through oral mucosa. As this route bypasses the hepatic first-pass metabolism it provides more consistent plasma nicotine levels compared smoking. Using nicotine polacrilex pouch results in, delivery of nicotine effectively without the harmful constituents of

tobacco combustion such as tar, carbon monoxide, and carcinogenic polycyclic aromatic hydrocarbons.

As per pharmaceuticals perspective, the nicotine polacrilex pouch shows several formulation advantages. It is a stable, portable, and discreet dosage form that enhances patient compliance, and usually a socially acceptable alternative to smoking or chewing tobacco.

Pharmacokinetically, nicotine polacrilex pouches show effective buccal absorption and moderate systemic bioavailability, giving sufficient plasma concentrations to reduce the cravings and withdrawal symptoms. The half-life of nicotine is approximately two hours, and its metabolism primarily occurs in them, with minor contributions from renal and pulmonary routes. There are minor side effects such as nausea, salivation, or mild dizziness that are generally self-limiting. However, despite their therapeutic effects, there are some limitations. The variability in nicotine release rates across different pouch brands and user techniques can influence pharmacokinetic consistency.

In summary, nicotine polacrilex pouches represent advancement in nicotine replacement therapy, by combining the pharmacological efficacy of nicotine polacrilex with a user-friendly and pharmaceutically efficient delivery system.

The controlled release of nicotine polacrilex pouch enhanced patient acceptability, and improved its potential make them a valuable and important addition amongst the NRT options. With continued research focusing on formulation optimization, clinical evaluation, and regulatory standardization, nicotine polacrilex pouches have a strong potential to convert the landscape of smoking cessation and harm reduction strategies. In the larger context of global public health, such innovations can be significant step toward minimizing tobacco-related illness and death through safer, patient-centered pharmacotherapeutic interventions.

References

1. e. a. (. Prakash, "Formulation and optimization of mucoadhesive buccal film for nicotine replacement therapy.," *International Journal of Applied Pharmaceutics*, vol. 15, no. 3, pp. 100-112, 2023.
2. C. P. N. O. P. & N. T. Pornpitchanarong, "Development and evaluation of nicotine buccal films for smoking cessation therapy.," *Journal of Drug Delivery Science and Technology*, p. 55, 2020.
3. G. N. B. E. A. D. M. M. T. J. M. F. H. G. Haswell LE, "Biomarkers of exposure and potential harm in exclusive users of electronic cigarettes and current, former, and never smokers.," *Intern Emerg Med.*, vol. 5, no. 18, pp. 1359-1371, Aug 2023 .
4. P. C. P. M. B. S. T. M. D. J. P. K. G. A. A. S. C. L. C. J. K. B. G. B. G. N. J. K. Kanobe MN, "Randomized crossover clinical studies to assess abuse liability and nicotine pharmacokinetics of Velo Oral Nicotine pouches," *Front Pharmacol*, Mar 2025.
5. M. M. et.al., "A Randomised Study to Investigate the Nicotine Pharmacokinetics of Oral Nicotine Pouches and a Combustible Cigarette.," *ur J Drug Metab Pharmacokinet*, vol. 2, no. 47, pp. 211-221, Mar 2022 .
6. S. Moldoveanu, "identification and Quantitation of Nicotine Polacrilex in Nicotine Pouches and Other Oral Nicotine Delivery Products," *Contributions to Tobacco & Nicotine Research*, vol. 3, pp. 43-49, 2023.
7. D. N. J. N. S. L. J. M. & L. G. Karine Renard, "Characterization of the nicotine uptake and safety of Nordic spirit tobacco-free oral nicotine pouches: A randomized cross-over study," *Springer Nature*, no. 242, p. 855–865, 2025.
8. M. S. R. K. T. V. S. M. C. N. R. K. T. J. N. T. O. G. Chapman F, "A randomised, open-label, cross-over clinical study to evaluate the pharmacokinetic, pharmacodynamic and safety and tolerability profiles of tobacco-free oral nicotine pouches relative to cigarettes.," *Psychopharmacology (Berl)*, vol. 9, no. 239, pp. 2931-2943, 2022.

9. R. A. C. T. C. R. Henningfield JE, "Drinking coffee and carbonated beverages blocks absorption of nicotine from nicotine polacrilex gum," JAMA.
10. J. a. M. E. a. V. L. a. P. A. a. P. W. Wilhelm, "the pH of Smokeless Tobacco Determines Nicotine Buccal Absorption: Results of a Randomized Crossover Trial," *Clinical Pharmacology & Therapeutics*, vol. 111, pp. 1066-1074, 2021.
11. D. G. P. V. T. e. a. Rungraungrayabkul, "What is the impact of nicotine pouches on oral health: a systematic review," *BMC Oral Health*, 2024.
12. P. R. J. W. Å. H. A. S. P. Olsson Gisleskog PO, "Nicotine Population Pharmacokinetics in Healthy Smokers after Intravenous, Oral, Buccal and Transdermal Administration," *Clin Pharmacokinet*, vol. 4, no. 60, pp. 541-561, 2021.
13. e. E. KA, "Trends and Patterns of Tobacco and Nicotine Product Use Among Youth in Canada, England, and the United States From 2017 to 2019," vol. 3, no. 69, pp. 447-456, 2021.
14. e. a. Chimel, "A Review of the Health Impact of Nicotine Pouches," *Quality in Sport*, vol. 57617, no. 37, pp. 2450-3118., 2025.